These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 19270153)

  • 21. Twice-daily amprenavir 1200 mg versus amprenavir 600 mg/ritonavir 100 mg, in combination with at least 2 other antiretroviral drugs, in HIV-1-infected patients.
    Nadler JP; Gathe JC; Pollard RB; Richmond GJ; Liao Q; Griffith S; Lancaster CT; Hernandez JE; Pappa KA;
    BMC Infect Dis; 2003 Jun; 3():10. PubMed ID: 12795812
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Atazanavir for treatment of HIV infection in clinical routine: efficacy, pharmacokinetics and safety.
    Feldt T; Oette M; Kroidl A; Göbels K; Leidel R; Sagir A; Kuschak D; Häussinger D
    Eur J Med Res; 2005 Jan; 10(1):7-10. PubMed ID: 15737947
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study.
    Molina JM; Lamarca A; Andrade-Villanueva J; Clotet B; Clumeck N; Liu YP; Zhong L; Margot N; Cheng AK; Chuck SL;
    Lancet Infect Dis; 2012 Jan; 12(1):27-35. PubMed ID: 22015077
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetics of the combination raltegravir/atazanavir in HIV-1-infected patients.
    Jansen A; Colbers EP; van der Ven AJ; Richter C; Rockstroh JK; Wasmuth JC; van Luin M; Burger DM
    HIV Med; 2013 Aug; 14(7):449-52. PubMed ID: 23506243
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Viro-immunologic response to ritonavir-boosted or unboosted atazanavir in a large cohort of multiply treated patients: the CARe Study.
    Santoro MM; Bertoli A; Lorenzini P; Lazzarin A; Esposito R; Carosi G; Di Perri G; Filice G; Moroni M; Rizzardini G; Caramello P; Maserati R; Narciso P; Cargnel A; Antinori A; Perno CF;
    AIDS Patient Care STDS; 2008 Jan; 22(1):7-16. PubMed ID: 18095835
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Clinical utility of atazanavir].
    Ribera Pascuet E; Curran A
    Enferm Infecc Microbiol Clin; 2008 Dec; 26 Suppl 17():55-67. PubMed ID: 20116619
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nevirapine-raltegravir combination, an NRTI and PI/r sparing regimen, as maintenance antiretroviral therapy in virologically suppressed HIV-1-infected patients.
    Reliquet V; Chirouze C; Allavena C; Muret P; Peytavin G; André-Garnier E; Bettinger D; Ferré V; Hoen B; Raffi F
    Antivir Ther; 2014; 19(1):117-23. PubMed ID: 24145365
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Once-daily dosing of saquinavir soft-gel capsules and ritonavir combination in HIV-1-infected patients (IMEA015 study).
    Lamotte C; Landman R; Peytavin G; Mentre F; Gerbe J; Brun-Vezinet F; Boue F; Spiridon G; Valantin MA; Michelet C; Farinotti R; Yeni P
    Antivir Ther; 2004 Apr; 9(2):247-56. PubMed ID: 15134187
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of baseline protease genotype and phenotype on HIV response to atazanavir/ritonavir in treatment-experienced patients.
    Naeger LK; Struble KA
    AIDS; 2006 Apr; 20(6):847-53. PubMed ID: 16549968
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Change to a once-daily combination including boosted atazanavir in HIV-1-infected children.
    Macassa E; Delaugerre C; Teglas JP; Jullien V; Tréluyer JM; Veber F; Rouzioux C; Blanche S
    Pediatr Infect Dis J; 2006 Sep; 25(9):809-14. PubMed ID: 16940839
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mid-dosing interval concentration of atazanavir and virological outcome in patients treated for HIV-1 infection.
    Fabbiani M; Di Giambenedetto S; Ragazzoni E; Colafigli M; Prosperi M; Cauda R; Navarra P; De Luca A
    HIV Med; 2010 May; 11(5):326-33. PubMed ID: 20070407
    [TBL] [Abstract][Full Text] [Related]  

  • 33. 96-week efficacy and safety of atazanavir, with and without ritonavir, in a HAART regimen in treatment-naive patients.
    Malan DR; Krantz E; David N; Rong Yang ; Mathew M; Iloeje UH; Jun Su ; McGrath D;
    J Int Assoc Physicians AIDS Care (Chic); 2010; 9(1):34-42. PubMed ID: 20071596
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and safety of indinavir/ritonavir 400/100 mg twice daily plus two nucleoside analogues in treatment-naive HIV-1-infected patients with CD4+ T-cell counts <200 cells/mm3: 96-week outcomes.
    Mootsikapun P; Chetchotisakd P; Anunnatsiri S; Boonyaprawit P
    Antivir Ther; 2005; 10(8):911-6. PubMed ID: 16430196
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and tolerability of a double boosted protease inhibitor (lopinavir + saquinavir/ritonavir) regimen in HIV-infected patients who failed treatment with nonnucleoside reverse transcriptase inhibitors.
    Chetchotisakd P; Anunnatsiri S; Mootsikapun P; Kiertiburanakul S; Anekthananon T; Bowonwatanuwong C; Kowadisaiburana B; Supparatpinyo K; Ruxrungtham K;
    HIV Med; 2007 Nov; 8(8):529-35. PubMed ID: 17944686
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Exposure-related effects of atazanavir on the pharmacokinetics of raltegravir in HIV-1-infected patients.
    Cattaneo D; Ripamonti D; Baldelli S; Cozzi V; Conti F; Clementi E
    Ther Drug Monit; 2010 Dec; 32(6):782-6. PubMed ID: 20926993
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of boosted and unboosted atazanavir-containing antiretroviral regimens in real life: results from a multicentre cohort study.
    Giuntini R; Martinelli C; Ricci E; Vichi F; Gianelli E; Madeddu G; Abeli C; Palvarini L; Penco G; Marconi P; Grosso C; Pellicano G; Bonfanti P; Quirino T
    HIV Med; 2010 Jan; 11(1):40-5. PubMed ID: 19686438
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Time to virological failure with atazanavir/ritonavir and lopinavir/ritonavir, with or without an H2-receptor blocker, not significantly different in HIV observational database study.
    Keiser PH; Nassar N
    Int J STD AIDS; 2008 Aug; 19(8):561-2. PubMed ID: 18663047
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Atazanavir and lopinavir/ritonavir: pharmacokinetics, safety and efficacy of a promising double-boosted protease inhibitor regimen.
    Ribera E; Azuaje C; Lopez RM; Diaz M; Feijoo M; Pou L; Crespo M; Curran A; Ocaña I; Pahissa A
    AIDS; 2006 May; 20(8):1131-9. PubMed ID: 16691064
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Efficacy of atazanavir in treatment-naive patients].
    Moreno S; Hernández B; Dronda F
    Enferm Infecc Microbiol Clin; 2008 Dec; 26 Suppl 17():9-13. PubMed ID: 20116611
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.